InVitro International: Expectations Remain High for Animal Welfare & Growth Opportunities
InVitro International (OTCQB: IVRO) reported its FY '24 financial results, showing mixed performance. The company achieved sales of $811,290, marking a 2.4% increase compared to FY '23, while net income significantly improved to $106,704 from $1,555 in the previous year. Fourth quarter performance showed sales growth of 19.9% reaching $221,200, although quarterly net income declined 48.8% to $25,122 compared to $49,035 in the same period last year. The company marked its 20th consecutive year of profits and expressed optimism about its M&A growth strategy and non-animal testing business prospects for FY '25.
InVitro International (OTCQB: IVRO) ha riportato i risultati finanziari per l'anno fiscale '24, mostrando una performance mista. L'azienda ha registrato vendite per 811.290 dollari, con un aumento del 2,4% rispetto all'anno fiscale '23, mentre il reddito netto è significativamente migliorato, raggiungendo 106.704 dollari rispetto a 1.555 dollari dell'anno precedente. La performance del quarto trimestre ha mostrato una crescita delle vendite del 19,9%, raggiungendo 221.200 dollari, sebbene il reddito netto trimestrale sia diminuito del 48,8%, scendendo a 25.122 dollari rispetto ai 49.035 dollari dello stesso periodo dell'anno scorso. L'azienda ha segnato il 20° anno consecutivo di profitti e ha espresso ottimismo riguardo alla sua strategia di crescita tramite fusioni e acquisizioni e alle prospettive del business di test non su animali per l'anno fiscale '25.
InVitro International (OTCQB: IVRO) informó sus resultados financieros del año fiscal '24, mostrando un rendimiento mixto. La empresa logró ventas de 811.290 dólares, marcando un aumento del 2,4% en comparación con el año fiscal '23, mientras que el ingreso neto mejoró significativamente a 106.704 dólares desde 1.555 dólares en el año anterior. El rendimiento del cuarto trimestre mostró un crecimiento en ventas del 19,9% alcanzando 221.200 dólares, aunque el ingreso neto trimestral disminuyó un 48,8% a 25.122 dólares en comparación con 49.035 dólares en el mismo período del año pasado. La empresa marcó su 20° año consecutivo de ganancias y expresó optimismo sobre su estrategia de crecimiento por medio de fusiones y adquisiciones y las perspectivas de negocios de pruebas no animales para el año fiscal '25.
InVitro International (OTCQB: IVRO)가 FY '24 재무 결과를 보고하며 혼합된 성과를 보였습니다. 회사는 811,290달러의 매출을 기록하여 FY '23에 비해 2.4% 증가했으며, 순이익이 크게 개선되었습니다: 1,555달러에서 106,704달러로 증가했습니다. 4분기 성과는 19.9%의 매출 성장을 보여주며 221,200달러에 도달했지만, 분기 순이익은 지난해 같은 기간의 49,035달러에 비해 48.8% 하락한 25,122달러로 나타났습니다. 이 회사는 연속 20년간의 이익을 기록하였고 FY '25에 대한 M&A 성장 전략과 비동물 테스트 사업 전망에 대해 낙관적인 입장을 보였습니다.
InVitro International (OTCQB: IVRO) a annoncé ses résultats financiers pour l'exercice '24, avec des performances mitigées. L'entreprise a réalisé un chiffre d'affaires de 811.290 dollars, marquant une augmentation de 2,4 % par rapport à l'exercice '23, tandis que le revenu net s'est nettement amélioré, passant de 1.555 dollars à 106.704 dollars par rapport à l'année précédente. La performance du quatrième trimestre a montré une croissance des ventes de 19,9 %, atteignant 221.200 dollars, bien que le revenu net trimestriel ait diminué de 48,8 % pour s'établir à 25.122 dollars, contre 49.035 dollars au même trimestre de l'année dernière. L'entreprise a marqué son 20e année consécutive de bénéfices et a exprimé son optimisme concernant sa stratégie de croissance par fusions et acquisitions et les perspectives de son activité de tests sans animaux pour l'exercice '25.
InVitro International (OTCQB: IVRO) hat die Finanzzahlen für das Geschäftsjahr '24 veröffentlicht und dabei eine gemischte Leistung gezeigt. Das Unternehmen erzielte Umsätze von 811.290 Dollar, was einem Anstieg von 2,4% im Vergleich zum Geschäftsjahr '23 entspricht, während sich der Nettoertrag erheblich verbesserte und von 1.555 auf 106.704 Dollar stieg. Die Leistung des vierten Quartals zeigte eine Umsatzsteigerung von 19,9% und erreichte 221.200 Dollar, obwohl der quartalsweise Nettoertrag um 48,8% auf 25.122 Dollar im Vergleich zu 49.035 Dollar im Vorjahreszeitraum zurückging. Das Unternehmen feierte sein 20. aufeinanderfolgendes Jahr mit Gewinnen und äußerte Optimismus hinsichtlich seiner M&A-Wachstumsstrategie und der Geschäftsaussichten für tierversuchsfreie Tests im Geschäftsjahr '25.
- Sales increased 2.4% to $811,290 in FY '24
- Net income significantly improved to $106,704 from $1,555
- Q4 sales grew 19.9% to $221,200
- Achieved 20th consecutive year of profitability
- Q4 net income declined 48.8% to $25,122
Placentia, California--(Newsfile Corp. - December 4, 2024) - Today InVitro International (OTCQB: IVRO) announced FY '24 sales of
While evaluating FY '24 financial results, CEO W. Richard Ulmer observed: "IVRO's Board of Directors is pleased with our 20th consecutive year of profits. They believe we're positioned well to begin execution of our M & A growth strategy. Expectations are high in FY '25 both for our core business of NON-Animal testing, and for animal welfare growth opportunities around the world. We believe IVRO can shine an even brighter light within that broadening path."
About InVitro International, Inc.
InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology-driven provider of non-animal testing methods. The Company's testing technologies are designed to produce data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services.
This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. These risks and uncertainties include but are not limited to acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update such statements.
Company Contact:
W. Richard Ulmer
Chief Executive Officer and Chairman
(800)246-8487
invitro@invitrointl.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232416
FAQ
What were InVitro International's (IVRO) FY 2024 financial results?
How did IVRO perform in Q4 2024?
What growth strategies is IVRO pursuing for FY 2025?
